Up in smoke? Vaping on the edge of banishment

Industry Insight
Jul.13.2022

The U.S. Food and Drug Administration (FDA) has paused a ban on the sale of Juul Labs’ e-cigarettes, saying it requires an additional review of the company’s marketing application.

 

This pause follows a federal appeals court’s decision a few weeks ago to stay — i.e. temporarily freeze — the FDA’s ban, following an appeal from Juul requesting an emergency review of the FDA’s order.

 

But the once-thriving company isn’t out of the woods just yet: The FDA has only paused the ban for reevaluation. It has not rescinded it.

 

Juul has always been in the spotlight, in part because of its prominent placement atop the e-cigarette chain, but with the company facing a potential demise, it could be the first casualty, with the rest of the vaping industry in the government’s sights.

 

Dr. Zubair Karim, assistant professor in the Department of Interdisciplinary Health Sciences at Augusta University, was a researcher on a study that looked at Juul e-cigarettes and how they elevate the risk of thrombosis and other complications in patients.

 

Up in smoke? Vaping on the edge of banishment

 

“Thrombosis is the formation of a blood clot, either partial or complete blockage, within blood vessels, whether venous or arterial, limiting the natural flow of blood,” Karim said.

 

“There are several complications depending on where the thrombosis is located. The most serious problems include stroke, heart attack and serious breathing problems, which is called pulmonary embolism. If the patients are not treated in a timely manner, it will lead to life-threatening conditions. However, progression of the disease can be prevented by following changes in our lifestyle such as increasing physical activity, quitting smoking, losing weight, eating a balanced diet, quitting junk food and managing other health conditions.”

 

With the ban on Juul products, could this result in a ban on other companies’ e-cigarette products as well, or was there something specifically about Juul that caused their ban?

 

“This is the first steps toward the banning of the e-cigarette, i.e., Juul, where the FDA took a significant and bold step,” Karim said.

 

“Gradually, this will open the path for banning of the other e-cigarette products. There are no differences in the Juul and other products, but Juul became more popular in our young generation. Many local and state jurisdictions have recently begun enacting laws that prohibit e-cigarette usage, although some state laws with comprehensive smoke-free laws will still allow for vaping to be permitted in bars and restaurants while prohibiting e-cigarettes in other indoor places.”

 

For years, e-cigarettes and vaping devices were seen as a “safer” alternative to traditional cigarettes, but with flavors and packaging that has attracted children to the fad, efforts have been renewed to look into the possible side effects.

 

“Both smoking and vaping have similar side effects and cause serious health risks in the long run. Scientists do not fully understand the long-term health effects of electronic cigarettes, yet science indicates that they are not a safe alternative to smoking,” said Karim.

 

“In the last several years it has been observed that vaping is growing in popularity among teenagers. Moreover, e-cigarettes contain a large dose of nicotine, a substance known to slow the development of brains in fetuses, children and teens. Furthermore, vaping involves breathing in aerosol that contains several chemicals, including nicotine and flavoring through an e-cigarette or other devices. Also, the liquid present in the e-cigarettes which creates the vapor is dangerous to adults and children if they swallow, inhale, or get it on the skin.

 

Nonetheless, vaping also delivers dangerous chemicals, including diacetyl, cancer-causing chemicals, heavy metals, volatile organic compounds, and such toxic chemicals that are not generated in traditional cigarettes. In summary, long-term vaping causes similar toxic impact to overall health compared to traditional cigarettes.”

 

The content excerpted or reproduced in this article comes from a third-party, and the copyright belongs to the original media and author. If any infringement is found, please contact us to delete it. Any entity or individual wishing to forward the information, please contact the author and refrain from forwarding directly from here.

GSTHR Estimates 200 Million People Use Non-Combustible Nicotine Products as 28 Countries Show Rising Use Alongside Falling Smoking Rates
GSTHR Estimates 200 Million People Use Non-Combustible Nicotine Products as 28 Countries Show Rising Use Alongside Falling Smoking Rates
The Global State of Tobacco Harm Reduction, a project operated by Knowledge·Action·Change, estimates that about 200 million people worldwide use non-combustible nicotine products including vapes, heated tobacco, nicotine pouches and snus. Its 2026 report says use of these products rose alongside declining smoking rates in 28 countries it analyzed. The data do not establish that all 200 million users have quit smoking, nor do they prove a direct causal relationship. GSTHR also says regulatory restrictions on the products continue to expand in many markets.
Sep.10
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
At the 2026 New Approaches Summit in New York, FDA Center for Tobacco Products Director Bret Koplow said the PMTA pathway is “predicated on tobacco harm reduction.” He outlined four CTP priorities: youth prevention, helping adults quit or switch to lower-risk products, improving relative-risk communication, and reducing unauthorized products. Koplow also addressed flavored e-cigarettes, public risk perceptions, industry credibility and efforts to make PMTA reviews more efficient and predictable.
Sep.26
Product | PMJ Adds Bold Ruby to IQOS ILUMA i Lineup in Japan, Convenience-Store Rollout Starts Sept. 29
Product | PMJ Adds Bold Ruby to IQOS ILUMA i Lineup in Japan, Convenience-Store Rollout Starts Sept. 29
Philip Morris Japan (PMJ) launched Bold Ruby as a new regular color for the IQOS ILUMA i and IQOS ILUMA i ONE in Japan on September 16, 2026, priced at JPY 6,980 and JPY 3,980, respectively. Initial sales began through IQOS online and physical channels, with convenience stores and selected tobacco retailers set to follow from September 29. Bold Ruby is a regular rather than limited-edition colorway and is available for the ILUMA i and ILUMA i ONE, but not the ILUMA i PRIME. The release does not involve changes to the devices' core hardware or functions.
Sep.22
HG Innovation, linked to IMiracle and ELFBAR, wins China patent for 6-methylnicotine salts covering vaping and oral products
HG Innovation, linked to IMiracle and ELFBAR, wins China patent for 6-methylnicotine salts covering vaping and oral products
HG Innovation Limited has been granted a Chinese invention patent covering 6-methylnicotine salt formulations and their use in oral and vaping products. The technology forms salts between 6-methylnicotine and alicyclic carboxylic acids, with granted claims extending to oral products, atomization substrates and electronic atomization devices. Applicant-generated tests reported differences in oxidation stability, in-vitro cytotoxicity and aerosol heavy-metal performance compared with selected benzoate or lactate controls. HG Innovation is directly linked to the broader IMiracle and ELFBAR business network.
Sep.04
2Firsts Interview | Cigarette Sales Fall as Smokeless Alternatives Gain in U.S. Convenience Stores, NACS Says
2Firsts Interview | Cigarette Sales Fall as Smokeless Alternatives Gain in U.S. Convenience Stores, NACS Says
Ahead of the 2026 NACS Show, 2Firsts interviewed Chris Rapanick, NACS managing director of research, on changes reshaping the U.S. convenience-store tobacco and nicotine market. NACS data show cigarette sales declining while smokeless alternatives, including nicotine pouches, continue to grow. The interview also examines higher OTP margins, shifting backbar space, weaker store traffic, regulatory uncertainty and NACS’ outlook for 2027, offering a retailer-side view of one of the world’s largest nicotine markets.
Interview
Oct.03
UK-Listed Consumer Goods Group Supreme Sees Vape Duty as Potential Consolidation Opportunity, Holds FY27 Outlook
UK-Listed Consumer Goods Group Supreme Sees Vape Duty as Potential Consolidation Opportunity, Holds FY27 Outlook
UK-listed consumer goods group Supreme plc says it continues to expect FY27 trading to meet market expectations as the Vaping Products Duty takes effect on October 1, while maintaining a comparatively positive view of the new tax and compliance regime. Supreme has said the framework could increase compliance complexity for smaller operators and contribute to market consolidation, while its manufacturing, compliance and distribution scale may allow it to gain share. Its 88Vape brand will retain its value positioning.
Sep.18